Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease

Journal of Rheumatology

Volumn 40, Issue 5, 2013, Pages 640-646

  Fischer, Aryeh ^a   Brown, Kevin K ^a   Du Bois, Roland M ^b   Frankel, Stephen K ^a   Cosgrove, Gregory P ^a   Fernandez Perez, Evans R ^a   Huie, Tristan J ^a   Krishnamoorthy, Mahalakshmi ^a   Meehan, Richard T ^a   Olson, Amy L ^a   Solomon, Joshua J ^a   Swigris, Jeffrey J ^a  

^a DEPARTMENT OF MEDICINE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Connective tissue disease; Interstitial lung disease; Mycophenolate mofetil

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CYTOPENIA; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; INFECTION; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION;

CONNECTIVE TISSUE DISEASE; INTERSTITIAL LUNG DISEASE; MYCOPHENOLATE MOFETIL;

CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PATIENT DROPOUTS; RESPIRATORY FUNCTION TESTS;

EID: 84876918697     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121043     Document Type: Article

References (11)

1. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70. (Pubitemid 44955900)
2. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
3. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-34. (Pubitemid 350127847)
4. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006;130:30-6. (Pubitemid 44116838)
5. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008;133:455-60. (Pubitemid 351272405)
6. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010;29:1167-8.
7. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Selva-O'Callaghan A, Solans-Laque R, Vilardell-Tarres M. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011;30:1393-8.
8. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008;102:150-5. (Pubitemid 350151821)
9. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009;337:329-35.
10. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006;45:1005-8. (Pubitemid 44283057)
11. Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: A call for clarification. Chest 2010;138:251-6.